Stigma CBD Oil is designed to be used as a sublingual tincture. Take a half dropper full or more and hold under your tongue for 30 seconds to a minute before swallowing. If preferred, the tincture can be immediately swallowed—a higher dosage is suggested if taken in this method.
To achieve maximum results, it is suggested that the chosen dosage is taken once or twice daily and with consistency.
Instructions for use (Gummies):
Stigma CBD gummies are designed for long lasting and saturating effect. Take one (10mg) or more gummies with each meal of the day. As the gummies and your food break down progressively throughout the day, the CBD will slowly be released into your bloodstream.
Instructions for use (Gel Caps):
Stigma Gel Caps are extra strength (25mg) and designed to be rapidly absorbed and released into the bloodstream for a concentrated effect.
Cannabidiol or CBD is a non-intoxicating component of the cannabis plant with therapeutic potential.
Unlike its sister molecule THC, CBD doesn’t make people feel “high” and has no noticeable psychoactive effect.
All of Stigma’s products are powered by naturally grown, CBD-rich American hemp.
Stigma’s CBD ingredient is in. the form of a full spectrum concentrate and is derived from the hemp plant material using only naturally occurring CO2 gas, pressure and temperature. This process is devoid of any harmful chemicals, fully non-toxic and given the lack of dangerous solvents involved is regarded as both safe and sustainable.
“Full spectrum” means Stigma’s products include not just CBD but also the other minor cannabinoids and fully array of medicinal compounds and phytochemicals found to naturally in the hemp cannabis plant.
Current, ongoing research and anecdotal user reports suggest that CBD-rich products may be helpful in easing symptoms of a wide range of conditions.
Scientists have noted that CBD seems to confer therapeutic benefits to the human body in many different ways by tapping into how we function physiologically and biologically on a deep level.
CBD is generally regarded by researchers as a very safe substance, but it can interact with some common pharmaceuticals. Please consult your physician if are taking other medications, pregnant or have concerns about how CBD may affect your health.
Forbes recently published a thoughtful piece about the legendary Jack Herer, father of modern cannabis activism (pictured above with Dennis Peron, who himself is as much a pillar of the cannabis movement as Jack) without whom our modern moment of sweeping decriminalization and legalization of cannabis and hemp use– medical, recreational and industrial– would not have occurred.
It occurs to us to wonder, however, what Jack would have thought about the intensive, nearly strangling controls that we have accepted in trade for the moderate legal tolerances we we have achieved for access to this benevolent plant. In an era of burdensome and costly licensing, regulation, batch tracking and child proofing that we all are blithely accepting in exchange for this tolerance, were Jack here right now he might be the one trying to remind us– like the charming and wonderful children’s educational book of the same title— that “it’s just a plant.”
The Native Americans have long been stalwart supporters of hemp cultivation. Without the eloquent activism of such strong presences as John Trudell, Winona LaDuke and others, the attachment of hemp cultivation to the US Farm Bill of 2018 would not have been a successful reality. Stigma Hemp is in solidarity with the Santee Sioux Tribe seeking their right to cultivate hemp in South Dakota and are hoping they achieve victory in court!
Mpls St. Paul Magazine recently featured Stigma in a well-done piece entitled “Is Everyone Taking CBD?” Spoiler alert: not everyone is taking CBD but in our opinion perhaps they should be! Give the article a read and let us know what you think.
Some updates on CBD’s status at the federal level from Vote Hemp:
“U.S. Senate Majority Leader Mitch McConnell (R-KY) met with Acting Food and Drug Administration (FDA) Commissioner Dr. Ned Sharpless yesterday. During the meeting, Senator McConnell discussed the importance of hemp production and the need for clarity from FDA on the sale of hemp derived CBD products. Senator McConnell informed Dr. Sharpless of the positive impact the legalization of hemp is having in Kentucky. He also reminded Dr. Sharpless of some of the ongoing challenges — such as the need for a regulatory framework for CBD — he hears about from hemp farmers, processors and manufacturers in the state. “While the 2018 Farm Bill included my provision to remove hemp, and its derivatives like CBD, from the list of controlled substances, CBD food and dietary supplement products remain in a gray area without clarification from the FDA,” Senator McConnell said. “Congress’ intent was clear with the passage of the Farm Bill that these products should be legal, and our farmers, producers and manufacturers need clarity as well as a workable pathway forward regarding the Agency’s enforcement and potential regulatory plans for certain CBD products. I appreciate Acting Commissioner Sharpless meeting with me today to discuss this important issue. Like my constituents, I am anxious to know the FDA’s plans to ensure public access to safe CBD products.”